Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution. - Wikidata - wikimedia - TriplyDB

Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution.

Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution.

http://www.wikidata.org/entity/Q35212575

about

Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121).Antibody Engineering & Therapeutics, the annual meeting of The Antibody Society December 7-10, 2015, San Diego, CA, USA.Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor models Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy.Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions.Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses.Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.Demystifying the cytokine network: Mathematical models point the way.Targeting Immunotherapy to the Tumor Microenvironment.Delivering safer immunotherapies for cancer.Genetically Engineered Multivalent Proteins for Targeted Immunotherapy.Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses.Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity.Antitumor Antibodies Can Drive Therapeutic T Cell Responses.Targeting cytokine therapy to the pancreatic tumor microenvironment using PD-L1 specific VHHs.IL-2 and Beyond in Cancer Immunotherapy.A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment.

P2860

Q28066935-D8A4E8A8-EF69-44DF-8342-874DF8C62253 Q28072319-1C651398-6F89-4BDE-B094-28394E823378 Q33705698-4646F4D4-C9B7-4FAB-B8BD-B2EBD654D2D4 Q33917876-42382534-2027-4490-9310-80DD26A39DE7 Q35933820-C744294C-0D16-48D4-8629-9B1A7CC737A3 Q36827406-2AFE99A0-5E58-4374-9522-8C5775DA9767 Q37281838-6F16E1F6-A07F-4631-BEF5-4A1B57C9F242 Q37485709-6216910B-0ABE-40E6-973C-4378ED088429 Q37554718-4C08577F-1F50-4926-943B-1D3FD0DF198B Q37741534-9CEBCA4C-484D-44CC-A10A-4C54E74C2B77 Q39029793-8551232A-DBF2-4EC5-825E-23221EC871CD Q39195213-14C199BC-E4A8-4832-992E-0AA4505A5A54 Q39330984-C693C221-71D4-4EC2-B1D6-2F7DDF90350F Q42416567-5A3560D7-5006-430D-A221-8ED9C616B8B6 Q44944214-97E2A0B1-521E-4C84-A62D-A560FA28AD54 Q47203993-9B1BE875-9571-4A19-9541-102BB87FAB22 Q47722599-B6ADC99B-9815-4ABB-80EA-79FB9A67D4EB Q49832296-14890C52-ADEE-494C-AC25-9D293C40BC93 Q50004232-DDF69085-8EA5-4BAA-B5AE-A61866FF290D Q50538951-FC909D21-CF40-405D-9374-CBE60A385084

P2860

Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution.

http://www.wikidata.org/entity/Q35212575

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution.

@ast

Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution.

@en

type

label

Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution.

@ast

Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution.

@en

prefLabel

Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution.

@ast

Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution.

@en

P1433

Q35212575-899C72BC-ADB8-4789-BEC9-9CD70F7770A1

P1476

Q35212575-5E52DACC-75F8-4346-8C6C-3B7DA8FF952C

P2093

Q35212575-1092EE88-031B-430B-B68C-301E0BAD3B4F

Q35212575-9C4BBE4E-4574-432C-B190-C4D79DDF8392

Q35212575-D653DFDF-4664-4392-9AFB-A318B50225A2

P2860

Q35212575-11F5EFB0-8877-45CD-8225-4AFF4AEE70E5

Q35212575-1CF505B7-D273-44B8-90AC-246BEEF07D5D

Q35212575-2853E6C3-D16B-4D5E-A99D-55F1152D4AB7

Q35212575-29409890-87E1-48D0-83ED-4C245EF00DA8

Q35212575-348C4D1A-C560-40C5-BF77-FE61993DF5CD

Q35212575-36756ACA-251D-49F3-9D20-9B814E3CDDB0

Q35212575-414FD80A-A03D-4186-AF0A-BFD77F44859E

Q35212575-416B2750-8CF8-41D7-9809-1754FBB63452

Q35212575-44310087-4CCF-461A-9B83-C33C21CBCC52

Q35212575-4B1B58FD-81D3-474D-950E-5350672FB41D

P304

Q35212575-129E9309-9751-4F14-ABB4-D5E55899AEE6

P31

Q35212575-05B7DDC0-AF66-4ECC-9037-6AED14877C42

P356

Q35212575-64B3313F-6765-48AD-A1A5-47DDD33D1F1E

P407

Q35212575-4EC16F21-802C-41A4-B0F3-33840F948A3A

P433

Q35212575-C445D159-CB5F-4236-BA80-7188AAEA1155

P478

Q35212575-1BA3A982-3645-4B5A-9E6B-E4974153C8D3

P50

Q35212575-512F9642-F31F-40CB-A941-BB3B7F950D31

Q35212575-ABF6DE4F-8F14-48E0-A838-EE86970CE052

P577

Q35212575-E9D18C42-0192-41D0-9599-E2CD2BFD63E3

P5875

Q35212575-FE63E930-7F83-46C9-8B5B-185032A7A507

P698

Q35212575-3437E60E-137D-46A7-BBFD-FBEC61B4595F

P932

Q35212575-069F6144-4737-456B-BBEA-097AD62CA34A

P356

PNAS.1416159112

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution.

@en

P2093

Byron H Kwan

http://www.w3.org/2001/XMLSchema#string

Cary F Opel

http://www.w3.org/2001/XMLSchema#string

Tejas Navaratna

http://www.w3.org/2001/XMLSchema#string

P2860

Identification and characterization of macrophage inflammatory protein 2

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

High efficiency cell-specific targeting of cytokine activity

Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice

Monoclonal antibodies: versatile platforms for cancer immunotherapy.

The role of interleukin-2 during homeostasis and activation of the immune system.

IL-2: the first effective immunotherapy for human cancer.

Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.

Mouse Phenome Database (MPD)

Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention.

P304

3320-3325

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1416159112

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-03-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273439819

http://www.w3.org/2001/XMLSchema#string

P698

25733854

http://www.w3.org/2001/XMLSchema#string

P932

4371941

http://www.w3.org/2001/XMLSchema#string